sitagliptin + vitamin D3

Sitagliptin + vitamin D3 is a combination therapy consisting of the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin and cholecalciferol (vitamin D3). This regimen, sometimes referred to as VIDPP-4i, has been studied primarily in patients with new-onset type 1 diabetes (T1D) and latent autoimmune diabetes in adults (LADA). The combination aims to prolong the partial remission ("honeymoon") phase by preserving residual beta-cell function. Mechanistically, sitagliptin inhibits DPP-4, increasing incretin levels and improving glycemic control, while vitamin D3 modulates immune responses and may reduce autoimmune destruction of pancreatic beta cells. Clinical studies suggest this combination is associated with longer clinical remission phases, improved C-peptide levels, reduced autoantibody titers, and anti-inflammatory effects such as decreased IFN-γ and IL-17 cytokines. The therapy has shown good tolerability in reported studies[1][2][3][5].

Other names

VIDPP-4iVIDPP4iVIDPP 4i